Analyst consensus rating
Neurocrine Biosciences Analyst Rating: Strong Buy
NBIX is rated Strong Buy by 27 analysts with a $211.57 target. As of 2026-08-28.
Direct answer
Neurocrine Biosciences's consensus rating is Strong Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $211.57.
Forecast evidence checked August 28, 2026.
Get free Neurocrine Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $153.84
- Average price target
- $211.57
- High price target
- $249.00
- Low price target
- $165.00
- Low target gap
- +7.3%
- Target upside
- +37.5%
- High target gap
- +61.9%
- Target range width
- 54.6%
- Consensus rating
- Strong Buy
- Analysts
- 27
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neurocrine Biosciences?
Neurocrine Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $211.57.
How far are Neurocrine Biosciences's low and high targets from the recorded price?
The low target implies +7.3%, while the high target implies +61.9%.
How many analysts are included in Neurocrine Biosciences's consensus?
The verified consensus includes 27 analysts.
How is Neurocrine Biosciences's target upside or downside calculated?
The average target of $211.57 is divided by the recorded price of $153.84, then one is subtracted to produce +37.5%. This does not guarantee a future return.
When was Neurocrine Biosciences's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.